<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003552</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066609</org_study_id>
    <secondary_id>NHLBI-98-H-0006</secondary_id>
    <nct_id>NCT00003552</nct_id>
    <nct_alias>NCT00001739</nct_alias>
  </id_info>
  <brief_title>Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Peripheral stem cell transplantation may allow doctors to give&#xD;
      higher doses of chemotherapy and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus peripheral stem&#xD;
      cell transplantation in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Identify an antitumor effect of allogeneic peripheral blood stem cell&#xD;
      transplantation (PBSCT) in patients with metastatic melanoma.&#xD;
&#xD;
      II. Evaluate the safety and toxicity of a nonmyeloablative, low intensity, preparative&#xD;
      regimen followed by an HLA-matched allogeneic PBSCT in these patients.&#xD;
&#xD;
      III. Monitor engraftment by measuring donor-recipient chimerism in lymphoid and myeloid&#xD;
      lineages in these patients.&#xD;
&#xD;
      IV. Investigate the relationship between donor-host chimerism and the incidence of acute and&#xD;
      chronic graft-versus-host disease in this patient population.&#xD;
&#xD;
      V. Investigate the effect of lymphocyte infusions on donor-host chimerism in this patient&#xD;
      population.&#xD;
&#xD;
      VI. Determine disease-free survival, overall survival, and mortality from the procedure or&#xD;
      tumor progression in this patient population.&#xD;
&#xD;
      PROTOCOL OUTLINE: This is a dose-escalation study of a conditioning regimen. Patients receive&#xD;
      1 of 3 dose levels of chemotherapy prior to peripheral blood progenitor cell (PBPC)&#xD;
      transplantation. Patients at dose level 1 receive cyclophosphamide IV over 1 hour on days -7&#xD;
      and -6 and fludarabine IV over 30 minutes daily on days -5 to -1. Patients at dose level 2&#xD;
      receive cyclophosphamide IV over 1 hour on days -7 and -6, fludarabine IV over 30 minutes&#xD;
      daily on days -5 to -1, and antithymocyte globulin daily on days -5 to -2. Patients at dose&#xD;
      level 3 receive cyclophosphamide IV over 1 hour daily on days -8 to -6, fludarabine IV over&#xD;
      30 minutes daily on days -5 to -1, and antithymocyte globulin daily on days -5 to -2.&#xD;
&#xD;
      Patients undergo mobilized CD34+ PBPC transplantation on day 0. PBPC transplantation may be&#xD;
      repeated on days 1 and 2 if deemed necessary.&#xD;
&#xD;
      Patients with progressive disease on days 15-30, day 60, or day 100, without&#xD;
      graft-versus-host disease, receive infusion(s) of donor lymphocytes. Further donor lymphocyte&#xD;
      infusions after day 100 may be given at the discretion of the attending physician.&#xD;
&#xD;
      Patients are followed every 2 months for 6 months, every 3 months for the next 2 years, and&#xD;
      then every 6 months until year 5 posttransplantation.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Stage IV Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Histologically confirmed metastatic melanoma not amenable to&#xD;
        complete surgical resection and progressive despite immunotherapy and/or chemotherapy&#xD;
        Bidimensionally evaluable clinically or radiographically HLA 6/6 or 5/6 matched sibling&#xD;
        donor available No CNS metastases --Prior/Concurrent Therapy-- See Disease Characteristics&#xD;
        At least 30 days since prior treatment for melanoma --Patient Characteristics-- Age: 18 to&#xD;
        60 Performance status: ECOG 0-1 Life expectancy: At least 3 months Hematopoietic: Not&#xD;
        specified Hepatic: Bilirubin no greater than 4 mg/dL Transaminases no greater than 3 times&#xD;
        upper limit of normal Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: Left&#xD;
        ventricular ejection fraction greater than 40% Pulmonary: DLCO greater than 65% of&#xD;
        predicted Other: HIV negative No major organ dysfunction precluding transplantation No&#xD;
        other malignancies except basal cell or squamous cell skin cancer No psychiatric disorder&#xD;
        or mental deficiency that would preclude study Not pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard W. Childs</last_name>
    <role>Study Chair</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Heart, Lung, and Blood Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>skin tumor</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage, melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

